Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Aditya A Mohan"'
Autor:
Mustafa Khasraw, John H Sampson, Kirit Singh, Kelly M Hotchkiss, Aditya A Mohan, Jessica L Reedy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/f3d546a2ae534a7cade485be9a02e111
Autor:
Mark Yarchoan, Aditya A Mohan, Lauren Dennison, Teena Vithayathil, Amanda Ruggieri, Gregory B Lesinski, Todd D Armstrong, Nilofer S Azad, Elizabeth M Jaffee
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0224600 (2019)
Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, MEK inhibitors have shown substantial acti
Externí odkaz:
https://doaj.org/article/deeb6c87dad04ce283915d1ea8fb3199
Publikováno v:
In Solar Energy 1 November 2023 264
Autor:
Aditya A. Mohan, BSc, Lyra B. Olson, PhD, Ibtehaj A. Naqvi, MD, PhD, Sarah A. Morrison, PhD, Bryan D. Kraft, MD, Lingye Chen, MD, Loretta G. Que, MD, Qing Ma, PhD, Christina E. Barkauskas, MD, Allan Kirk, MD, PhD, Smita K. Nair, PhD, Bruce A. Sullenger, PhD, George Kasotakis, MD, MPH
Publikováno v:
Critical Care Explorations, Vol 4, Iss 12, p e0799 (2022)
OBJECTIVES:. The COVID-19 pandemic has claimed over eight hundred thousand lives in the United States alone, with older individuals and those with comorbidities being at higher risk of severe disease and death. Although severe acute respiratory syndr
Externí odkaz:
https://doaj.org/article/dc9548d080d84b5c94caf1198546cf58
Autor:
Aditya A. Mohan, William H. Tomaszewski, Aden P. Haskell-Mendoza, Kelly M. Hotchkiss, Kirit Singh, Jessica L. Reedy, Peter E. Fecci, John H. Sampson, Mustafa Khasraw
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We have only recently begun to understand how cancer metabolism affects antitumor responses and immunotherapy outcomes. Certain immunometabolic targets have been actively pursued in other tumor types, however, glioblastoma research has been slow to e
Externí odkaz:
https://doaj.org/article/fde8852ef67c421689dcd357438a1646
Autor:
Angela Y. Jia MD, PhD, Aleksandra Popovic BS, Aditya A. Mohan BS, Jane Zorzi BS, Paige Griffith MSN, AG-ACNP, BSN, Amy K. Kim MD, Robert A. Anders MD, PhD, Richard A. Burkhart MD, Kelly Lafaro MD, MPH, Christos Georgiades MD, PhD, Nilofer S. Azad MD, Robert P. Liddell MD, Marina Baretti MD, Ihab R. Kamel MD, PhD, Amol Narang MD, Mark Yarchoan MD, Jeffrey Meyer MD
Publikováno v:
Cancer Control, Vol 28 (2021)
Multidisciplinary care has been associated with improved survival in patients with primary liver cancers. We report the practice patterns and real world clinical outcomes for patients presenting to the Johns Hopkins Hospital (JHH) multidisciplinary l
Externí odkaz:
https://doaj.org/article/034223e2cef847608ca5c19b928d6819
Publikováno v:
Cancers. 15:2856
Gliomas are the most common primary brain malignancy and are universally fatal. Despite significant breakthrough in understanding tumor biology, treatment breakthroughs have been limited. There is a growing appreciation that major limitations on effe
Autor:
Mark Yarchoan, Leslie Cope, Amanda N. Ruggieri, Robert A. Anders, Anne M. Noonan, Laura W. Goff, Lipika Goyal, Jill Lacy, Daneng Li, Anuj K. Patel, Aiwu R. He, Ghassan K. Abou-Alfa, Kristen Spencer, Edward J. Kim, S. Lindsey Davis, Autumn J. McRee, Paul R. Kunk, Subir Goyal, Yuan Liu, Lauren Dennison, Stephanie Xavier, Aditya A. Mohan, Qingfeng Zhu, Andrea Wang-Gillam, Andrew Poklepovic, Helen X. Chen, Elad Sharon, Gregory B. Lesinski, Nilofer S. Azad
Publikováno v:
J Clin Invest
The Journal of clinical investigation, vol 131, iss 24
The Journal of clinical investigation, vol 131, iss 24
BACKGROUND: MEK inhibitors have limited activity in biliary tract cancers (BTCs) as monotherapy but are hypothesized to enhance responses to programmed death ligand 1 (PD-L1) inhibition. METHODS: This open-label phase II study randomized patients wit
Autor:
Hotchkiss KM; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, USA., Batich KA; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, USA., Mohan A; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, USA., Rahman R; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Piantadosi S; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA(S.P.)., Khasraw M; Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, USA.
Publikováno v:
Neuro-oncology [Neuro Oncol] 2023 Oct 03; Vol. 25 (10), pp. 1752-1762.
Autor:
Zaidi SE; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA.; School of Medicine, University of Paris Cité, Paris, France., Moelker E; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Singh K; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Mohan A; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Salgado MA; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Essibayi MA; Department of Neurosurgery, Albert Einstein College of Medicine, Bronx, NY, USA.; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Hotchkiss K; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Shen S; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Lee W; University of North Carolina, Chapel Hill, NC, USA., Sampson J; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA., Khasraw M; Department of Neurosurgery, Duke University Medical Center, Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA. mustafa.khasraw@duke.edu.
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2023 Jul; Vol. 37 (4), pp. 489-503. Date of Electronic Publication: 2023 May 31.